logo
Plus   Neg
Share
Email

Bayer HealthCare To Evaluate Riociguat In New Indication - Quick Facts

Bayer HealthCare, a subsidiary of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), announced the start of a randomized, double-blind, placebo-controlled Phase IIb study. The RISE-IIP study or Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias is designed to investigate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension or PH associated with idiopathic interstitial pneumonia or IIP.

According to the company, the RISE-IIP trial will be carried out at more than 50 sites in 11 countries and will enroll approximately 120 patients. The study is designed as a 'signal-generating'study which may help to better understand the disease and the effect of riociguat on it. Based on the results, further steps will be decided.

Pulmonary hypertension or PH is a severe, progressive, life-changing and life-threatening disorder of the heart and lungs in which the blood pressure in the pulmonary arteries is above normal, and which can lead to heart failure and death.

Pulmonary Hypertension associated with Idiopathic Interstitial Pneumonia (PH-IIP) is a rare disease in which patients suffer both from pulmonary hypertension and idiopathic interstitial pneumonia or IIP.

Riociguat is a soluble guanylate cyclase or sGC stimulator, the first member of a novel class of compounds, discovered and developed by Bayer as an oral treatment to target a key molecular mechanism underlying PH. Riociguat is being investigated as a new and specific approach to treat different types of PH. sGC is an enzyme found in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme enhances synthesis of the signaling molecule cyclic guanosine monophosphate or cGMP. cGMP plays an important role in regulating vascular tone, proliferation, fibrosis, and inflammation.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Reigniting concerns about a global trade war, President Donald Trump announced plans to impose new tariffs on billions of dollars worth of Chinese imports on Friday. Trump said in a statement the U.S. will implement a 25 percent tariff on $50 billion of goods from China that contain "industrially significant technologies." Investors may want to take note of shares of school bus maker Blue Bird Corp. (BLBD) that are 17% off their 52-week high of $24.99, and at an attractive price point. Significant growth potential in Alternative-Fuel offerings, product differentiation & upgrades, compelling industry attributes, growing profitability, rising interest in Electric Buses, and strong Free cash flow generation make this s A full-time minimum wage worker cannot afford a two-bedroom rental apartment anywhere in the U.S. despite the increase in state and city minimum wages, according to report from the National Low Income Housing Coalition or NLIHC. The NLIHC's "Out of Reach" 2018 annual report calculates the gap between wages and the costs of rental housing across the U.S.
Follow RTT